{
  "ticker": "JNJ",
  "target_date": "2025-07-24",
  "actual_date": "2025-07-24",
  "collected_at": "2025-12-08T12:03:18.032019",
  "price": {
    "open": 167.2,
    "high": 167.69,
    "low": 166.59,
    "close": 167.2624969482422,
    "volume": 6636900,
    "change_1d_pct": 0.27,
    "change_7d_pct": 9.27,
    "change_30d_pct": 8.38
  },
  "technicals": {
    "rsi_14": 78.62,
    "sma_20": 156.89,
    "sma_50": 153.11,
    "macd": 3.684,
    "macd_signal": 2.411,
    "macd_histogram": 1.274,
    "bb_upper": 168.09,
    "bb_lower": 145.7,
    "price_vs_sma20_pct": 6.61,
    "price_vs_sma50_pct": 9.24,
    "volume_ratio": 0.76
  },
  "fundamentals": {
    "market_cap": 488894169088,
    "pe_ratio": 19.586874,
    "forward_pe": 19.143394,
    "price_to_book": 6.1589828,
    "price_to_sales": 5.3054748,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.35,
    "pct_from_52w_low": 44.24
  },
  "macro": {
    "spy": {
      "price": 632.67,
      "change_1d_pct": 0.03,
      "change_7d_pct": 1.63
    },
    "vix": {
      "level": 15.39,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.41
    },
    "dollar_index": {
      "level": 97.38
    },
    "gold": {
      "price": 3371.0
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate",
      "source": "Yahoo",
      "datetime": 1753376923,
      "summary": "AstraZeneca Plc (NASDAQ:AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gMG). The trial enrolled 260 patients. MG is a chronic autoimmune disorder that causes muscle weakness a",
      "url": "https://finnhub.io/api/news?id=3517e509b2206d2e92358226a89c67b92774ea23c8c87e3935af1edabdaef0c8"
    },
    {
      "headline": "Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term",
      "source": "Yahoo",
      "datetime": 1753365001,
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=fa5cbdac47356c7f9027098e504789c3fa65f66d00a95158bd197db897fb3dd2"
    },
    {
      "headline": "J&J Innovative Medicine Unit Shines Again in Q2: Will This Continue?",
      "source": "Yahoo",
      "datetime": 1753363380,
      "summary": "JNJ's Innovative Medicine unit posts solid Q2 growth despite Stelara's LOE, powered by Darzalex, Tremfya, Erleada and new drugs.",
      "url": "https://finnhub.io/api/news?id=b0c003928b0c797247e577d10b0d8ddb4ff152a4becfbdf922189047918cab24"
    },
    {
      "headline": "Johnson & Johnson showcases latest advancements in Alzheimer's research at AAIC 2025",
      "source": "Yahoo",
      "datetime": 1753358400,
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced promising new data from its Alzheimer's disease (AD) research program will be presented at the Alzheimer's Association International Conference (AAIC), taking place July 27\u201331 in Toronto, Canada. Across 12 abstracts, the Company will share insight into h",
      "url": "https://finnhub.io/api/news?id=f87356dbcfa45a2295bb862c1442adc3292e8c9b4e213162cec9f8794e03998c"
    },
    {
      "headline": "Low IV Alert: Stocks that Could be Ready to Pop",
      "source": "Yahoo",
      "datetime": 1753354802,
      "summary": "Market volatility has dropped since the April correction, but with plenty of items on the news front, we could see a volatility spike at any point.",
      "url": "https://finnhub.io/api/news?id=d44991cee97fb85efba395dcf43e3cd3bd07b8610ecae05636e1e45e2801ce22"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "10-Q",
      "date": "2025-07-24",
      "description": "jnj-20250629.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000178/jnj-20250629.htm"
    },
    {
      "form": "13F-HR",
      "date": "2025-07-22",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445425000367/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "4",
      "date": "2025-07-18",
      "description": "xslF345X05/wk-form4_1752869553.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000172/xslF345X05/wk-form4_1752869553.xml"
    },
    {
      "form": "8-K",
      "date": "2025-07-16",
      "description": "jnj-20250716.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000170/jnj-20250716.htm"
    },
    {
      "form": "4",
      "date": "2025-06-12",
      "description": "xslF345X05/wk-form4_1749760336.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000156/xslF345X05/wk-form4_1749760336.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}